376 related articles for article (PubMed ID: 29334605)
21. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
[TBL] [Abstract][Full Text] [Related]
23. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Huang PY; Cao KJ; Guo X; Mo HY; Guo L; Xiang YQ; Deng MQ; Qiu F; Cao SM; Guo Y; Zhang L; Li NW; Sun R; Chen QY; Luo DH; Hua YJ; Mai HQ; Hong MH
Oral Oncol; 2012 Oct; 48(10):1038-1044. PubMed ID: 22591726
[TBL] [Abstract][Full Text] [Related]
26. Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.
Wang YW; Ho SY; Lee SW; Chen CC; Litsu S; Huang WT; Yang CC; Lin CH; Chen HY; Lin LC
Int J Med Sci; 2020; 17(5):568-576. PubMed ID: 32210706
[No Abstract] [Full Text] [Related]
27. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
[TBL] [Abstract][Full Text] [Related]
28. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
[TBL] [Abstract][Full Text] [Related]
29. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
30. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
[TBL] [Abstract][Full Text] [Related]
31. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
Zang J; Li C; Xu M; Xu W; Kang X; Wang J; Luo S; Shi M
Sci Rep; 2018 Sep; 8(1):13318. PubMed ID: 30190563
[TBL] [Abstract][Full Text] [Related]
32. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
33. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
34. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
Wang C; Tang X; Wang J; Song J; Xu Y
Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
[TBL] [Abstract][Full Text] [Related]
35. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials.
Chen YP; Tang LL; Yang Q; Poh SS; Hui EP; Chan ATC; Ong WS; Tan T; Wee J; Li WF; Chen L; Ma BBY; Tong M; Tan SH; Cheah SL; Fong KW; Sommat K; Soong YL; Guo Y; Lin AH; Sun Y; Hong MH; Cao SM; Chen MY; Ma J
Clin Cancer Res; 2018 Apr; 24(8):1824-1833. PubMed ID: 29431618
[No Abstract] [Full Text] [Related]
36. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J
Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514
[TBL] [Abstract][Full Text] [Related]
37. Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
Wen DW; Li ZX; Chen FP; Lin L; Peng BY; Kou J; Zheng WH; Yang XL; Xu SS; Sun Y; Zhou GQ
Oral Oncol; 2020 Aug; 107():104675. PubMed ID: 32361563
[TBL] [Abstract][Full Text] [Related]
38. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
Zhang Y; Li WF; Liu X; Chen L; Sun R; Sun Y; Liu Q; Ma J
Radiother Oncol; 2018 Oct; 129(1):18-22. PubMed ID: 29258695
[TBL] [Abstract][Full Text] [Related]
39. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a treatment in patients with locoregionally advanced nasopharyngeal carcinoma (LANC) involving carotid artery invasion.
Liu K; Wang Y; Ma L; Yang S; Zhang X
Eur Arch Otorhinolaryngol; 2022 Dec; 279(12):5791-5799. PubMed ID: 35918541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
